title: Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone.
abstract: OBJECTIVE
  To assess short-term efficacy and safety of intravitreal bevacizumab injections for idiopathic choroidal neovascularization (CNV) refractory to posterior subtenon triamcinolone injections.
  
  
  METHODS
  Noncomparative, interventional case series.
  
  
  METHODS
  Intravitreal bevacizumab was injected into 10 eyes with idiopathic CNV in which posterior subtenon triamcinolone injections were not efficacious for more than three months. The main outcome measures were changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and fluorescein angiography findings before and after bevacizumab injection.
  
  
  RESULTS
  After treatment, the BCVA improvement at one month (P = .029) continued to three months (P = .003). CRT decreased significantly (P < .001). Leakage from idiopathic CNV three months after treatment stopped in seven eyes, decreased in two, and continued in one. In one patient, conjunctival swelling developed after the injection but resolved and did not recur after another injection. No other complications developed.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab improves BCVA in eyes with idiopathic CNV refractory to triamcinolone.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, Osaka, Japan. fgomi@ophthal.med.osaka-u.ac.jp
authors.forename: Fumi
authors.initials: F
authors.lastname: Gomi
authors.forename: Kentaro
authors.initials: K
authors.lastname: Nishida
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oshima
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Miki
authors.initials: M
authors.lastname: Sawa
authors.forename: Motokazu
authors.initials: M
authors.lastname: Tsujikawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008297:Male; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide